# Evaluation Of SB-751689 Administered At Supratherapeutic Dose Levels In Healthy Adult Subjects.

> **NCT00468689** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 15 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** SB-751689 oral tablets (100 and 400 ng)
- **DRUG:** Ketoconazole (NIZORAL) oral tablets (200 mg)

## Key facts

- **NCT ID:** NCT00468689
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2008-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00468689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00468689, "Evaluation Of SB-751689 Administered At Supratherapeutic Dose Levels In Healthy Adult Subjects.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00468689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*